Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Deferred Shares Deferred Shares [Member] Represents information pertaining to deferred shares. Title of 12(b) Security Title of 12(b) Security Document Fiscal Year Focus Document Fiscal Year Focus Transaction-related legal and advisory fees Business Combination, Acquisition-Related Cost, Expense Vested and deferred (in usd per share) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period, Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period, Weighted Average Grant Date Fair Value Adjustment to Compensation, Amount Adjustment to Compensation Amount Number of Shares Underlying RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Segment Reporting [Abstract] Ordinary shares, £0.000025 nominal value; as at June 30, 2026 40,848,893 shares authorized, issued and outstanding and as at December 31, 2025 Common Stock, Value, Issued 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Entity Ex Transition Period Entity Ex Transition Period Restatement Determination Date Restatement Determination Date Total direct research and development expenses Direct Research And Development Expense Direct Research And Development Expense Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] Deferred Income [Table] Deferred Income [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Developed technology Developed Technology Rights [Member] Foreign Currency Translation in General and Administrative Expenses Foreign Currency Disclosure [Text Block] Percentage of ordinary shares present to exercise preemptive rights Percentage Of Shares Necessary To Exercise Preemptive Rights The minimum percentage of shares required to exercise preemptive rights. Related Party Transactions Related Party Transactions Disclosure [Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Property, Plant, and Equipment [Abstract] Property, Plant, and Equipment [Abstract] Entity Address, State or Province Entity Address, State or Province Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross PEO Total Compensation Amount PEO Total Compensation Amount Other comprehensive (loss)/gain – foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Ordinary shares, nominal value (in gbp per share) Ordinary shares, nominal value (per share) Common Stock, Par or Stated Value Per Share Topco Becaon Topco, Inc [Member] Becaon Topco, Inc Non-current liabilities: Liabilities, Noncurrent [Abstract] Intangible assets, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Unvested beginning balance (in shares) Unvested ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Change In indirect research and development expenses Change In Indirect Research And Development Expense, Current Period Compared To Prior Period Change In Indirect Research And Development Expense, Current Period Compared To Prior Period Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Weighted-average ordinary shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Expenses Expenses [Member] Expenses Total current liabilities Liabilities, Current 2030 Lessee, Operating Lease, Liability, to be Paid, Year Four Maryland MARYLAND Deferred shares, outstanding (in shares) Deferred Stock, Shares Outstanding Number of shares of deferred stock outstanding. Deferred income Increase (Decrease) in Deferred Revenue Entity Address, City or Town Entity Address, City or Town Awards granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Document Information [Line Items] Document Information [Line Items] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Class of Stock [Axis] Class of Stock [Axis] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ordinary shares, liquidation preference Ordinary Shares, Liquidation Preference The amount of liquidation preference on ordinary shares to be paid after which the deferred shares have the entitlement to receive out of the assets of the Company. Accumulated amortization for amortizable intangible assets Intangible Asset, Finite-Lived, Accumulated Amortization Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] United States UNITED STATES Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Number of depositary shares per share of common stock (in shares) Number Of Depositary Shares Per Share Of Common Stock Number Of Depositary Shares Per Share Of Common Stock Recently issued accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Enterprise Management Incentive Share Option Scheme Enterprise Management Incentive Share Option Scheme [Member] Information pertaining to the Enterprise Management Incentive Share Option Scheme. Schedule of Accrued Expenses and Other Current Liabilities Accrued Liabilities And Other Current Liabilities [Table Text Block] Tabular disclosure of the components of accrued liabilities and other current liabilities. Schedule of Significant Segment Expenses Segment Reporting [Table Text Block] Profit on sale of property and equipment Gain on sale of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Noncontrolling Interest Noncontrolling Interest [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Schedule of Change in Financial Instruments Classified within Level 3 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Property and Equipment, Net Property, Plant, and Equipment [Text Block] Schedule of Maturities of Minimum Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Options forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Deferred Income [Roll Forward] Deferred Income [Roll Forward] Net cash provided by/(used) in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Maximum period to exercise preemptive rights Period Of Preemptive Rights To Be Exercised The period allowed to exercise preemptive rights. 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two Ordinary Shares Equity [Text Block] Security Exchange Name Security Exchange Name Total indirect research and development expenses Indirect Research And Development Expense Indirect Research And Development Expense Weighted average exercise price of options granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Deferred shares, authorized (in shares) Deferred Stock, Shares Authorized The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws. Grant date fair value of awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Entity Shell Company Entity Shell Company Change in fair value recognized in net loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Research and Development of Immunotherapies and Vaccines Research And Development Of Immunotherapies And Vaccines [Member] Research And Development Of Immunotherapies And Vaccines Operating lease liability - current Lease liability, current Operating Lease, Liability, Current Non-cash lease expenses Non-Cash Lease Expenses The amount of non-cash lease expenses. Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Accrued Expenses and Other Current Liabilities Accrued Liabilities And Other Current Liabilities [Text Block] The entire disclosure of the components of accrued liabilities and other current liabilities. Earnings Per Share [Abstract] Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Geographical [Domain] Geographical [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Unrecognized compensation cost related to options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Change in research and development expenses Change In Research And Development Expense, Current Period Compared To Prior Period Change In Research And Development Expense, Current Period Compared To Prior Period Related Party Transactions [Abstract] Related Party Transactions [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Weighted-average ordinary shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Deferred shares, nominal value (in gbp per share) Deferred Stock, Par Or Stated Value Per Share Face amount or stated value per share of deferred stock. Number of geographic regions where the company operates Number Of Geographic Regions In Which Entity Operates Number Of Geographic Regions In Which Entity Operates Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Operating cash flows from operating leases Operating Lease, Payments Award Timing Predetermined Award Timing Predetermined [Flag] Restricted cash Restricted Cash, Current Intangible Asset, Goodwill and Other [Abstract] Intangible Asset, Goodwill and Other [Abstract] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Estimated annual amortization expense for 2026 Finite-Lived Intangible Asset, Expected Amortization, Current Year Finite-Lived Intangible Asset, Expected Amortization, Current Year Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Unvested beginning balance (in usd per share) Unvested ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value All Executive Categories All Executive Categories [Member] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Preferred stock par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Depreciation expense Depreciation Plan Name [Domain] Plan Name [Domain] Scenario [Domain] Scenario [Domain] Weighted average exercise price of options outstanding (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Right of use assets, net Right-of-use asset Operating Lease, Right-of-Use Asset Vested but subject to deferred settlement (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number Change in direct research and development expenses Change In Direct Research And Development Expense, Current Period Compared To Prior Period Change In Direct Research And Development Expense, Current Period Compared To Prior Period Schedule of Computation of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Segment information Segment Reporting [Text Block] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Vested and settled (in usd per share) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period, Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period, Weighted Average Grant Date Fair Value Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Research and development incentives receivable Increase (Decrease) in Research and Development Incentives Receivable Amount of increase (decrease) in research and development incentives receivable. Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Total stockholders’ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Deferred A shares, £1 nominal value; as at June 30, 2026 63,443 shares authorized, issued and outstanding and as at December 31, 2025 Deferred Stock, Value Issued Aggregate par or stated value of issued deferred stock. Maximum aggregate nominal amount of shares authorized to be allotted free from pre-emption rights Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre-emption Rights Amount of maximum aggregate nominal amount of shares that the board of directors are authorized to allot free from statutory Pre-emption rights. Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Other income/(expense): Other Income and Expenses [Abstract] Clywedog Clywedog Therapeutics, Inc. [Member] Clywedog Therapeutics, Inc. Ordinary shares, authorized (in shares) Common Stock, Shares Authorized Accrued payroll and employee benefits Accrued Employee Benefits, Current Schedule of Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Exercise Price Award Exercise Price CASH FLOWS FROM INVESTING ACTIVITIES: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Related Party Transaction [Axis] Related Party Transaction [Axis] Segment Reporting [Line Items] Segment Reporting [Line Items] Self-tender offer authorized amount to purchase Share Repurchase Program, Authorized, Amount Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Effect of exchange rates on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Schedule of Long-Lived Assets Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Long-Lived Asset [Table Text Block] Facility related Facility Related [Member] Facility Related Scenario [Axis] Scenario [Axis] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Deferred income reclassification to accrual Deferred Income, Reclassification To Accrual Deferred Income, Reclassification To Accrual Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adoption Date Trading Arrangement Adoption Date Direct research and development expenses: Direct Research and Development Expenses [Abstract] Direct Research and Development Expenses Foreign exchange translation Deferred Income, Foreign Exchange Translation Gain (Loss) Deferred Income, Foreign Exchange Translation Gain (Loss) Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders Equity, Attributable to Parent Total other income, net Nonoperating Income (Expense) ASSETS Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Total lease liability Operating Lease, Liability Insider Trading Policies and Procedures [Line Items] Options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Schedule of Changes in Deferred Income Deferred Income [Table Text Block] Other operating income Other Operating Income Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Additions to property and equipment Property, Plant, and Equipment, before Accumulated Depreciation, Addition Prepaid expenses and other current assets Total Prepaid Expense and Other Assets, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Number of reportable segments not disclosed flag Number Of Reportable Segments Not Disclosed Flag Number Of Reportable Segments Not Disclosed Flag Deferred tax benefit Deferred Income Tax Expense (Benefit) VTP-1000 Celiac VTP-1000 Celiac [Member] VTP-1000 Celiac Business Combination [Domain] Business Combination [Domain] Refundable security deposit Security Deposit Noncash proceeds from sale of property and equipment Noncash or Part Noncash Divestiture, Amount of Consideration Received Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Shares issuable for stock options that were excluded from the computation of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of Operating Segments RSUs Restricted Stock Units (RSUs) [Member] Central Index Key Entity Central Index Key All Adjustments to Compensation All Adjustments to Compensation [Member] Business Combination [Axis] Business Combination [Axis] Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Vested and deferred (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Deferred In Period Stock conversion ratio Stock Conversion Ratio Stock Conversion Ratio Income Statement [Abstract] Income Statement [Abstract] Document Transition Report Document Transition Report Other indirect costs Other Indirect Costs [Member] Other Indirect Costs Share Repurchase Program [Table] Share Repurchase Program [Table] Operating expenses Operating Expenses [Abstract] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Weighted-Average Assumptions of Fair Value Stock Option Issued to Employees Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Other operating income recognized related to the Funding Agreement Deferred Income, Revenue Recognized City Area Code City Area Code Schedule of Right-of-use Assets, Lease Liabilities and Other Information Lessee Operating Lease Right of Use asset and Other Information [Table Text Block] Tabular disclosure for Company's right-of-use asset and lease liability and other information. Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Document Information [Table] Document Information [Table] All Individuals All Individuals [Member] Name Forgone Recovery, Individual Name Weighted-average period over which unrecognized compensation cost is expected to be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Deferred Shares Stockholders Equity Deferred Shares Disclosure [Text Block] The entire disclosure for Deferred Shares as disclosed by the entity. Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] In-License Agreements In-License Agreements [Member] Represents the information pertaining to In-License Agreements. Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Intangible Assets, Net Intangible Asset [Text Block] Statement [Line Items] Statement [Line Items] Total assets Assets Entity [Domain] Entity [Domain] Weighted-average grant date fair value of options granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Interest expense Interest Expense, Nonoperating Share-Based Compensation Share-Based Payment Arrangement [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Issue of ordinary shares, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] Share based compensation expense Share-Based Payment Arrangement, Expense Other non-current liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Payables and Accruals [Abstract] Accumulated Deficit Retained Earnings [Member] Operating lease liability - non-current Lease liability, non-current Operating Lease, Liability, Noncurrent Total operating expenses Operating Expenses Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Ordinary shares, outstanding (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Deferred income Beginning balance Ending balance Deferred Income Net loss per share attributable to ordinary shareholders, diluted (in usd per share) Earnings Per Share, Diluted Vested and settled (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Settled In Period Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Value Added Tax receivable Value Added Tax Receivable, Current Amortization expense for intangible assets Intangible Asset, Finite-Lived, Amortization Expense Accumulated other comprehensive loss – foreign currency translation adjustments Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Intangible Assets, net Intangible Asset, Finite-Lived [Line Items] Research and development Total research and development expenses Research and Development Expense Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Outstanding (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Grant Date Fair Value IPO IPO [Member] Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Accrued manufacturing and clinical expenses Accrued Manufacturing and Clinical Expenses, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Intangible Asset, Finite-Lived, Class [Axis] Intangible Asset, Finite-Lived, Class [Axis] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Share Repurchase Program [Line Items] Share Repurchase Program [Line Items] Underlying Securities Award Underlying Securities Amount Comprehensive loss/(gain) attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Research and Development Type [Axis] Research and Development Type [Axis] Research and Development Type Issue of ordinary shares, net of issuance costs Stock Issued During Period, Value, New Issues Prepayments Prepaid Expense, Current Deferred shares, issued (in shares) Deferred Stock, Shares Issued Total number of deferred shares of an entity that have been sold or granted to shareholders Oxfordshire Oxfordshire [Member] Oxfordshire Issue of shares from the exercise of stock options Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Research and development incentives Research And Development Incentive Income (Expense) Represents the research and development incentives (expenses) for the period. Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Non-cash interest expense Non-Cash Interest Expense On Convertible Loan Notes Amount of non-cash interest expense on convertible loan notes. Segment Reporting [Table] Segment Reporting [Table] Scheme Shares Scheme Shares [Member] Scheme Shares Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Sale of Stock [Axis] Sale of Stock [Axis] Schedule of Lease Cost Lease, Cost [Table Text Block] Other Other Assets, Current Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Contingent consideration liability Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Loss from operations Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date Percentage of future royalties for direct sales of a covered product Percentage of Future Royalties for Direct Sales of Covered Product , License Agreement Percentage of future royalties for direct sales of a covered product under the In-License Agreements. Number of votes per common share (in votes) Common Stock Number of Votes Per Share The number of votes that each common share is entitled. Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Related Party Transaction [Domain] Related Party Transaction [Domain] Long-lived assets Long-Lived Asset, Excluding Financial Instrument, Customer Relationship, Mortgage Servicing Right, Deferred Policy Acquisition Cost, and Deferred Tax Asset, Amount Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Vested but subject to deferred settlement (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value Prepaid Expenses and Other Current Assets Prepaid Expense and Other Assets, Current [Text Block] The entire disclosure on prepaid expense and other current assets. Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Ordinary shares, issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Equity Components [Axis] Equity Components [Axis] Product and Service [Domain] Product and Service [Domain] American Depositary Shares ADR [Member] Entity Interactive Data Current Entity Interactive Data Current Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Net loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Deferred tax liability, net Deferred Income Tax Liabilities, Net Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Termination Date Trading Arrangement Termination Date Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Amount of lessee's undiscounted obligation for lease payment for operating lease due in year four and after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Settlement payments related to contingent consideration liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Document Type Document Type Foreign Currency [Abstract] Foreign Currency [Abstract] Fair Value as of Grant Date Award Grant Date Fair Value Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Deferred income Deferred Income, Current Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Loss before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies (Note 15) Commitments and Contingencies Gross amount of amortizable intangible assets Intangible Asset, Finite-Lived, before Accumulated Amortization Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Estimated annual amortization expense for 2030 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Counterparty Name [Axis] Counterparty Name [Axis] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Other Commitments [Table] Other Commitments [Table] Intangible Asset, Finite-Lived, Class [Domain] Intangible Asset, Finite-Lived, Class [Domain] Avidea Avidea [Member] This member stands for Avidea. Award Type [Domain] Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Remainder of 2026 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Fair Value Fair Value Disclosures [Text Block] Research and development incentives receivable Research And Development Incentives Receivable Amount of research and development incentives receivable. Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Estimated annual amortization expense for 2027 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One PEO Name PEO Name Geographical [Axis] Geographical [Axis] Other assets Other Assets Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Accrued grant repayment Accrued Grant Repayment, Current Accrued Grant Repayment, Current Legal Entity [Axis] Legal Entity [Axis] Net payments received for allowable sublicenses of technology developed Percentage Of Net Payments Received For Allowable Sublicenses Of Technology Developed License Agreement Percentage of net payments received for allowable sublicenses of technology developed under the In-License Agreements. Other Commitments [Line Items] Other Commitments [Line Items] Cash, cash equivalents and restricted cash, beginning of the period Cash, cash equivalents and restricted cash, end of the period Cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Accrued professional fees Accrued Professional Fees, Current Accounts payable Increase (Decrease) in Accounts Payable Oxford University Innovation Limited Oxford University Innovation Limited [Member] Represents the information pertaining to Oxford University Innovation Limited. Accrued other Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Nature of Business and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Share based compensation Share-Based Payment Arrangement, Noncash Expense Estimated annual amortization expense for 2028 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two Number of new subsidiaries Number Of New Subsidiaries Number Of New Subsidiaries Total lease cost Lease, Cost Sales of property and equipment Property, Plant, and Equipment, before Accumulated Depreciation, Disposition Amounts of related party transactions Related Party Transaction, Amounts of Transaction Net loss per share attributable to ordinary shareholders, basic (in usd per share) Earnings Per Share, Basic Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Merger agreement extension period Merger Agreement, Extension Period Merger Agreement, Extension Period Change in contingent consideration Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Ordinary shares Ordinary Shares Common Stock [Member] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Operating leases Operating Lease, Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate United Kingdom UNITED KINGDOM Maximum funding amount Funding Amount, Maximum Funding Amount, Maximum Equity Awards Adjustments Equity Awards Adjustments [Member] Coalition for Epidemic Preparedness Innovations Coalition For Epidemic Preparedness Innovations [Member] Coalition For Epidemic Preparedness Innovations Total liabilities and stockholders’ equity Liabilities and Equity Deferred Income [Line Items] Deferred Income [Line Items] Stock options Share-Based Payment Arrangement, Option [Member] Schedule of Company’s Long-Lived Assets Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table] Noncontrolling interest Equity, Attributable to Noncontrolling Interest Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Plan Name [Axis] Plan Name [Axis] Tabular List, Table Tabular List [Table Text Block] Additional paid-in capital Additional Paid in Capital Schedule of Share Based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Other income Other Nonoperating Income (Expense) Estimated annual amortization expense for 2031 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Five Total stockholders’ equity attributable to Barinthus Biotherapeutics plc stockholders Parent [Member] Estimated annual amortization expense for 2029 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three Name Awards Close in Time to MNPI Disclosures, Individual Name Stockholders’ equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period General and administrative General and Administrative Expense Accrued bonus Accrued Bonuses, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Other information Other Information, Lessee [Abstract] Other Information, Lessee Class of Stock [Domain] Class of Stock [Domain] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Personnel-related (including share-based compensation) Personnel Related [Member] Personnel Related Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Name Measure Name Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-in-Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Size of space under lease agreement (in square feet) Number Of Square Feet Under Lease Agreement Represents the information pertaining to number of Square Feet Under Lease Agreement. Cash payment Deferred Income, Cash Payment Deferred Income, Cash Payment Name Trading Arrangement, Individual Name Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Cash and cash equivalents Cash and Cash Equivalent Company Selected Measure Amount Company Selected Measure Amount Outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Depreciation and amortization Depreciation, Depletion and Amortization Entity Address, Address Line Two Entity Address, Address Line Two Net loss Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Barinthus legacy assets Barinthus Legacy Assets [Member] Barinthus Legacy Assets Weighted average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Tax benefit Income Tax Expense (Benefit) Net foreign exchange gain (loss) Gain (Loss), Foreign Currency Transaction, before Tax Grant Income Other Operating Income and Expense [Text Block] Award Timing Method Award Timing Method [Text Block] Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forecast Forecast [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Maximum additional contingent consideration payments upon achievement of milestones Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount Numerator: Net Income (Loss) Attributable to Parent [Abstract] Clywedog Capital Stock Clywedog Capital Stock [Member] Clywedog Capital Stock Net loss attributable to Barinthus Biotherapeutics plc shareholders Net Income (Loss) Attributable to Parent Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Proceeds from sale of property and equipment Proceeds from sale of equipment Proceeds from Sale of Property, Plant, and Equipment Statement [Table] Statement [Table] Restatement Determination Date: Restatement Determination Date [Axis] Accrued expenses and other current liabilities Total Accrued Liabilities and Other Liabilities, Current Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Interest income Investment Income, Interest Research and Development Type [Domain] Research and Development Type [Domain] Research and Development Type [Domain] Foreign exchange translation recognized in other comprehensive loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Unrealized foreign exchange (gain)/loss Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Indirect research and development expenses: Indirect Research and Development Expenses [Abstract] Indirect Research and Development Expenses Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block]